Speciality: Hematology
Description:
Welcome to our podcast. Today, we're breaking down blood clotting disorders—a group of conditions that affect how your blood forms clots. Normally, clotting stops bleeding when you’re injured. But with these disorders, the process can be too slow or too fast. Haemophilia, for example, makes it hard for blood to clot, leading to excessive bleeding. On the other hand, conditions like deep vein thrombosis cause clots to form too easily, increasing the risk of blockages in blood vessels. Both types can be serious and require medical attention. Understanding the signs, such as unexplained bruising or swelling, is crucial. If you notice these symptoms, consult your doctor. Early diagnosis and treatment make a big difference. Thanks for listening.
See More Webinars @ Hidoc Webinars
1.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
2.
Novel ADC Improves Survival in Metastatic TNBC
3.
New Data Put ADCs on the Map in Relapsed SCLC
4.
Breast cancer: Why it's difficult to treat and what new approaches are on the horizon
5.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
1.
Preventing Cancer-Associated Cachexia Through Early Muscle Proteolysis Signature Monitoring
2.
Pediatric Advances in Mapping Hematopoietic Development During Childhood
3.
Pathophysiology of Bone-Marrow Fibrotic Remodeling
4.
Hematopoietic Aging Signatures and Future Hematologic Disease Risk
5.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Blood Clotting Disorders Explained
2.
When Unexplained Bruising May Require Blood Testing
3.
Understanding Blood Clotting Disorders
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation